Stakeholders Urge Major Changes To Australia's PBS Listing Guidelines
This article was originally published in SRA
Executive Summary
The future shape of Australia's system for listing medicines on the Pharmaceutical Benefits Scheme is becoming clearer after the government published stakeholder responses to a consultation on the long-awaited review of the Pharmaceutical Benefits Advisory Committee guidelines, which are used by the pharmaceutical industry to prepare requests for PBS listing1,2.
You may also be interested in...
Australian Industry Concerned Over Comparator Drug, Differing Evidence Levels, As New PBS Guidance Draws Near
The revised guidelines for making submissions to list drugs on the Australian Pharmaceutical Benefits Scheme have raised industry and patient concerns over the criteria for choosing the comparator drug, how to assess differing levels of evidence, and the need for more patient and clinician input.
Changes To EU Pharma Reform: More Questions Than Answers?
In the first of a series of articles on the future direction of the EU pharmaceutical reform proposals, the Pink Sheet looks at the new uncertainties created for the drug industry after the European Parliament voted through a series of amendments in the area of regulatory data protection.
Post-Brexit UK Risks Being ‘Left Out In The Cold’ As EU Coordinates Action On Shortages
The UK is not alone in experiencing drug shortages, as data from across Europe show, but its departure from the EU makes it more difficult to respond to supply chain pressures, according to new research.